Market closedNon-fractional

Karyopharm Therapeutics/KPTI

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Ticker

KPTI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Newton, United States

Employees

325

KPTI Metrics

BasicAdvanced
$102M
Market cap
-
P/E ratio
-$1.28
EPS
0.25
Beta
-
Dividend rate
$102M
0.25
3.036
2.75
-180.811
-182.839
-5.53%
-31.21%
136.68%
0.669
-0.56
-0.56
-0.798
-5.16%
-26.66%
7.46%
-22.32%

What the Analysts think about KPTI

Analyst Ratings

Majority rating from 7 analysts.
Buy

KPTI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-112.68% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$33M
-1.78%
Net income
-$37M
-10.77%
Profit margin
-112.68%
-9.15%

KPTI Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 4.15%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.29
-$0.30
-$0.36
-$0.32
-
Expected
-$0.34
-$0.28
-$0.31
-$0.33
-$0.31
Surprise
-15.26%
7.14%
16.24%
-4.15%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Karyopharm Therapeutics stock?

Karyopharm Therapeutics (KPTI) has a market cap of $102M as of July 06, 2024.

What is the P/E ratio for Karyopharm Therapeutics stock?

The price to earnings (P/E) ratio for Karyopharm Therapeutics (KPTI) stock is 0 as of July 06, 2024.

Does Karyopharm Therapeutics stock pay dividends?

No, Karyopharm Therapeutics (KPTI) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Karyopharm Therapeutics dividend payment date?

Karyopharm Therapeutics (KPTI) stock does not pay dividends to its shareholders.

What is the beta indicator for Karyopharm Therapeutics?

Karyopharm Therapeutics (KPTI) has a beta rating of 0.25. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Karyopharm Therapeutics stock

Buy or sell Karyopharm Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing